blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3450434

EP3450434 - DEUTERATED DERIVATIVES OF RUXOLITINIB [Right-click to bookmark this link]
StatusThe patent has been granted
Status updated on  22.01.2021
Database last updated on 14.09.2024
FormerGrant of patent is intended
Status updated on  19.11.2020
FormerRequest for examination was made
Status updated on  09.10.2020
FormerGrant of patent is intended
Status updated on  08.07.2020
FormerRequest for examination was made
Status updated on  13.09.2019
FormerThe application has been published
Status updated on  01.02.2019
Most recent event   Tooltip13.09.2024Lapse of the patent in a contracting state
New state(s): MT		published on 16.10.2024 [2024/42]
Applicant(s)For all designated states
Sun Pharmaceutical Industries, Inc.
2 Independence Way
Princeton, NJ 08540 / US
[2023/37]
Former [2019/36]For all designated states
CoNCERT Pharmaceuticals, Inc.
65 Hayden Avenue, Suite 3000N
Lexington, MA 02421 / US
Former [2019/10]For all designated states
Concert Pharmaceuticals Inc.
99 Hayden Avenue, Suite 500
Lexington, MA 02421 / US
Inventor(s)01 / SILVERMAN, I. Robert
36 Orvis Road
Arlington, MA 02474 / US
02 / LIU, Julie F.
3 Whitman Circle
Lexington, MA 02420 / US
03 / MORGAN, Adam J.
14 Oak Ridge Lane
Ashland, MA 01721 / US
04 / PANDYA, Bhaumik
325 Springs Road
Bedford, MA 01730 / US
05 / HARBESON, Scott L.
355 Shore Dr
Ellenton, FL 34222-2025 / US
 [2021/11]
Former [2019/10]01 / SILVERMAN, I. Robert
36 Orvis Road
Arlington, MA 02474 / US
02 / LIU, Julie F.
3 Whitman Circle
Lexington, MA 02420 / US
03 / MORGAN, Adam J.
14 Oak Ridge Lane
Ashland, MA 01721 / US
04 / PANDYA, Bhaumik
28 Silk Street
Arlington, MA 02474 / US
05 / HARBESON, Scott L.
355 Shore Dr
Ellenton, FL 34222-2025 / US
Representative(s)Gill Jennings & Every LLP
The Broadgate Tower
20 Primrose Street
London EC2A 2ES / GB
[N/P]
Former [2019/10]Snodin, Michael D.
Park Grove IP
BioCity Nottingham
Pennyfoot Street
Nottingham NG1 1GF / GB
Application number, filing date18188152.514.06.2013
[2019/10]
Priority number, dateUS201261660428P15.06.2012         Original published format: US 201261660428 P
US201261678795P02.08.2012         Original published format: US 201261678795 P
[2019/10]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3450434
Date:06.03.2019
Language:EN
[2019/10]
Type: B1 Patent specification 
No.:EP3450434
Date:24.02.2021
Language:EN
[2021/08]
Search report(s)(Supplementary) European search report - dispatched on:EP10.12.2018
ClassificationIPC:C07D487/04, C07B59/00, A61K31/519, A61P35/02
[2019/10]
CPC:
C07D487/04 (EP); A61P35/02 (EP); C07B2200/05 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/42]
Former [2019/10]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
Extension statesBA06.09.2019
ME06.09.2019
TitleGerman:DEUTERIERTE DERIVATE VON RUXOLITINIB[2019/10]
English:DEUTERATED DERIVATIVES OF RUXOLITINIB[2019/10]
French:DÉRIVÉS DEUTÉRÉS DE RUXOLITINIB[2019/10]
Examination procedure06.09.2019Examination requested  [2019/42]
06.09.2019Date on which the examining division has become responsible
17.10.2019Despatch of communication that the application is deemed to be withdrawn, reason: reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report not received in time
27.12.2019Amendment by applicant (claims and/or description)
09.07.2020Communication of intention to grant the patent
07.10.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
20.11.2020Communication of intention to grant the patent
12.01.2021Fee for grant paid
12.01.2021Fee for publishing/printing paid
12.01.2021Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP13732046.1  / EP2861600
Divisional application(s)EP21156398.6  / EP3882249
Opposition(s)Opponent(s)01  23.11.2021  25.11.2021  ADMISSIBLE
INCYTE CORPORATION
1801 Augustine Cut-Off
Wilmington DE 19803 / US
Opponent's representative
Carpmaels & Ransford LLP
One Southampton Row
London WC1B 5HA / GB
 [2021/52]
deletedDeletion: Legal effect of rejection of opposition [ N /P ]
09.12.2021Invitation to proprietor to file observations on the notice of opposition
19.04.2022Reply of patent proprietor to notice(s) of opposition
17.01.2024Date of oral proceedings
12.02.2024Despatch of minutes of oral proceedings
12.02.2024Date of despatch of rejection of opposition
Appeal following opposition27.03.2024Appeal received No.  T0472/24
27.03.2024Payment of appeal fee
12.06.2024Statement of grounds filed
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
27.12.2019Request for further processing filed
27.12.2019Full payment received (date of receipt of payment)
Request granted
13.01.2020Decision despatched
Fees paidRenewal fee
09.08.2018Renewal fee patent year 03
09.08.2018Renewal fee patent year 04
09.08.2018Renewal fee patent year 05
09.08.2018Renewal fee patent year 06
27.06.2019Renewal fee patent year 07
29.06.2020Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU14.06.2013
AL24.02.2021
CY24.02.2021
CZ24.02.2021
EE24.02.2021
FI24.02.2021
HR24.02.2021
LT24.02.2021
LV24.02.2021
MC24.02.2021
MK24.02.2021
MT24.02.2021
RO24.02.2021
RS24.02.2021
SI24.02.2021
SK24.02.2021
SM24.02.2021
BG24.05.2021
GR25.05.2021
LU14.06.2021
IS24.06.2021
PT24.06.2021
[2024/42]
Former [2024/23]HU14.06.2013
AL24.02.2021
CY24.02.2021
CZ24.02.2021
EE24.02.2021
FI24.02.2021
HR24.02.2021
LT24.02.2021
LV24.02.2021
MC24.02.2021
MK24.02.2021
RO24.02.2021
RS24.02.2021
SI24.02.2021
SK24.02.2021
SM24.02.2021
BG24.05.2021
GR25.05.2021
LU14.06.2021
IS24.06.2021
PT24.06.2021
Former [2023/33]HU14.06.2013
AL24.02.2021
CY24.02.2021
CZ24.02.2021
EE24.02.2021
FI24.02.2021
HR24.02.2021
LT24.02.2021
LV24.02.2021
MC24.02.2021
RO24.02.2021
RS24.02.2021
SI24.02.2021
SK24.02.2021
SM24.02.2021
BG24.05.2021
GR25.05.2021
LU14.06.2021
IS24.06.2021
PT24.06.2021
Former [2023/30]AL24.02.2021
CY24.02.2021
CZ24.02.2021
EE24.02.2021
FI24.02.2021
HR24.02.2021
LT24.02.2021
LV24.02.2021
MC24.02.2021
RO24.02.2021
RS24.02.2021
SI24.02.2021
SK24.02.2021
SM24.02.2021
BG24.05.2021
GR25.05.2021
LU14.06.2021
IS24.06.2021
PT24.06.2021
Former [2022/23]AL24.02.2021
CZ24.02.2021
EE24.02.2021
FI24.02.2021
HR24.02.2021
LT24.02.2021
LV24.02.2021
MC24.02.2021
RO24.02.2021
RS24.02.2021
SI24.02.2021
SK24.02.2021
SM24.02.2021
BG24.05.2021
GR25.05.2021
LU14.06.2021
IS24.06.2021
PT24.06.2021
Former [2022/18]AL24.02.2021
CZ24.02.2021
EE24.02.2021
FI24.02.2021
HR24.02.2021
LT24.02.2021
LV24.02.2021
MC24.02.2021
RO24.02.2021
RS24.02.2021
SI24.02.2021
SK24.02.2021
SM24.02.2021
BG24.05.2021
GR25.05.2021
LU14.06.2021
PT24.06.2021
IS24.12.2021
Former [2022/13]AL24.02.2021
CZ24.02.2021
EE24.02.2021
FI24.02.2021
HR24.02.2021
LT24.02.2021
LV24.02.2021
MC24.02.2021
RO24.02.2021
RS24.02.2021
SI24.02.2021
SK24.02.2021
SM24.02.2021
BG24.05.2021
GR25.05.2021
PT24.06.2021
IS24.12.2021
Former [2022/10]AL24.02.2021
CZ24.02.2021
EE24.02.2021
FI24.02.2021
HR24.02.2021
LT24.02.2021
LV24.02.2021
MC24.02.2021
RO24.02.2021
RS24.02.2021
SK24.02.2021
SM24.02.2021
BG24.05.2021
GR25.05.2021
PT24.06.2021
IS24.12.2021
Former [2022/07]AL24.02.2021
CZ24.02.2021
EE24.02.2021
FI24.02.2021
HR24.02.2021
LT24.02.2021
LV24.02.2021
MC24.02.2021
RO24.02.2021
RS24.02.2021
SK24.02.2021
SM24.02.2021
BG24.05.2021
GR25.05.2021
IS24.06.2021
PT24.06.2021
Former [2021/50]CZ24.02.2021
EE24.02.2021
FI24.02.2021
HR24.02.2021
LT24.02.2021
LV24.02.2021
RO24.02.2021
RS24.02.2021
SK24.02.2021
SM24.02.2021
BG24.05.2021
GR25.05.2021
IS24.06.2021
PT24.06.2021
Former [2021/48]CZ24.02.2021
EE24.02.2021
FI24.02.2021
HR24.02.2021
LT24.02.2021
LV24.02.2021
RS24.02.2021
SM24.02.2021
BG24.05.2021
GR25.05.2021
IS24.06.2021
PT24.06.2021
Former [2021/46]FI24.02.2021
HR24.02.2021
LT24.02.2021
LV24.02.2021
RS24.02.2021
SM24.02.2021
BG24.05.2021
GR25.05.2021
IS24.06.2021
PT24.06.2021
Former [2021/42]FI24.02.2021
HR24.02.2021
LT24.02.2021
LV24.02.2021
RS24.02.2021
BG24.05.2021
GR25.05.2021
IS24.06.2021
PT24.06.2021
Former [2021/37]FI24.02.2021
HR24.02.2021
LT24.02.2021
LV24.02.2021
RS24.02.2021
BG24.05.2021
GR25.05.2021
PT24.06.2021
Former [2021/36]FI24.02.2021
HR24.02.2021
LT24.02.2021
BG24.05.2021
GR25.05.2021
PT24.06.2021
Former [2021/35]FI24.02.2021
HR24.02.2021
LT24.02.2021
PT24.06.2021
Former [2021/33]FI24.02.2021
LT24.02.2021
PT24.06.2021
Documents cited:Search[IDY]US2007135461  (RODGERS JAMES D [US], et al) [ID] 1-12 * Abstract; claims; pages 38-39, paragraph 0320; page 61: example 67. * [Y] 1-12;
 [Y]  - OSTOJIC ET AL., "Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis", FUTURE ONCOLOGY, (20110101), vol. 7, no. 9, doi:10.2217/FON.11.81, ISSN 1479-6694, pages 1035 - 1043, XP008150477 [Y] 1-12 * the whole document *

DOI:   http://dx.doi.org/10.2217/fon.11.81
 [YD]  - SHILLING ET AL., "Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans", DRUG METABOLISM AND DISPOSITION, (20101101), vol. 38, no. 11, doi:10.1124/dmd.110.033787, ISSN 0090-9556, pages 2023 - 2031, XP055071854 [YD] 1-12 * Page 2016, right column 1st sentence; page 2028, figure 2; page 2030, left column to right column, paragraph 1. *

DOI:   http://dx.doi.org/10.1124/dmd.110.033787
 [L]  - BUTEAU, "Deuterated Drugs: Unexpectedly Nonobvious?", vol. X, no. 1, ISSN 1536-7983, (20090101), pages 22 - 74, JOURNAL OF HIGH TECHNOLOGY LAW, SUFFOLK UNIVERSITY LAW SCHOOL, US, URL: http://www.law.suffolk.edu/highlights/stuorgs/jhtl/docs/pdf/Buteau_10JHTL1.pdf, (20090101), XP002636702 [L] 1-12 * Page 62, footnotes 248, 249 on predictability and obviousness; paragraph bridging pages 64-65; page 69, paragraph 2; page 72, last sentence to page 73, end of paragraph 1. Cited as common general knowledge. *
ExaminationWO2014078486
    - EMA/465846/2012: CHMP assessment report for Jakavi, 19 April 2012, 84 pages.
    - "Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis Patients", (20110422), URL: https://clinicaltrials.gov/ct2/show/NCT01340651
by applicantUS5304121
 US5886026
 US6099562
 US6803031
 US7014866
 US2006079502
 US2006094744
 US2008312258
 US7598257
 WO2010083283
    - KEMPF, D.J. et al., Antimicrobial agents and chemotherapy, (19970000), vol. 41, no. 3, pages 654 - 60
    - WANG, L et al., Clinical Pharmacology and Therapeutics, (19940000), vol. 56, no. 6, pages 659 - 67
    - BLAKE, MI et al., J Pharm Sci, (19750000), vol. 64, pages 367 - 91
    - FOSTER, AB, Adv Drug Res, (19850000), vol. 14, pages 1 - 40
    - KUSHNER, DJ et al., Can J Physiol Pharmacol, (19990000), pages 79 - 88
    - FISHER, MB et al., Curr Opin Drug Discov Devel, (20060000), vol. 9, pages 101 - 09
    - FUKUTO et al., J. Med. Chem., (19910000), vol. 34, pages 2871 - 76
    - SHILLING, A.D. et al., Drug Metabolism and Disposition, (20100000), vol. 38, no. 11, pages 2023 - 2031
    - WADA, E et al., Seikagaku, (19940000), vol. 66, page 15
    - GANNES, LZ et al., Comp Biochem Physiol Mol Integr Physiol, (19980000), vol. 119, page 725
    - Organic Letters, (20090000), vol. 11, no. 9, pages 1999 - 2009
    - LIN, Q. et al., Org. Lett., (20090000), vol. 11, page 1999
    - FREIREICH et al., Cancer Chemother. Rep, (19660000), vol. 50, page 219
    - Scientific Tables, Geigy Pharmaceuticals, (19700000), page 537
    - LIN, Q. et al., Org. Lett., (20090000), vol. 11, pages 1999 - 2002
OppositionUS2007135461
 US7855204
 WO2013188783
    - Ostojic Alen; Vrhovac Radovan; Verstovsek Srdan, "Ruxolitinib: a new JAK1/2 inhibitor that offers promising options for treatment of myelofibrosis", FUTURE ONCOLOGY, FUTURE MEDICINE LTD., LONDON, GB, GB , (20110101), vol. 7, no. 9, doi:10.2217/fon.11.81, ISSN 1479-6694, pages 1035 - 1043, XP008150477

DOI:   http://dx.doi.org/10.2217/fon.11.81
    - A. D. Shilling, F. M. Nedza, T. Emm, S. Diamond, E. Mckeever, N. Punwani, W. Williams, A. Arvanitis, L. G. Galya, M. Li, S. Shepard, J. Rodgers, T.-Y. Yue, S. Yeleswaram, "Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans", Drug Metabolism and Disposition, ¬American Society for Pharmacology and Experimental Therapeutics, etc.|, (20101101), vol. 38, no. 11, doi:10.1124/dmd.110.033787, ISSN 00909556, pages 2023 - 2031, XP055071854

DOI:   http://dx.doi.org/10.1124/dmd.110.033787
    - BUTEAU K C, "Deuterated Drugs: Unexpectedly Nonobvious?", JOURNAL OF HIGH TECHNOLOGY LAW, SUFFOLK UNIVERSITY LAW SCHOOL,, US, US , (20090101), vol. X, no. 1, ISSN 1536-7983, pages 22 - 74, XP002636702
    - A. YARNELL, "Heavy-Hydrogen Drugs Turn Heads, Again", Chem. Eng. News, (20090000), vol. 87, no. 25, pages 36 - 39, XP002546075
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.